Cerus Corporation

NASDAQ:CERS

Medical - Devices

Healthcare
$1.94 +2.92%

+$0.08 today

Market cap
$391.79M
Beta
1.77
P/E (TTM)
-53.8
EPS (TTM)
-$0.05
52W Low $1.15High $3.15

Volume 6.09M

Average 2.33M

CERS Depreciation & Amortization

Non-cash expense that spreads the cost of physical and intangible assets over their useful lives.

Cerus CorporationNASDAQ: CERS

Depreciation & Amortization · Q1 FY2026 · quarter ended Mar 2026

Depreciation & amortization grows, but more slowly than its trailing trend

Q1 FY2026 depreciation & amortization of $447K rose 45.6% year over year, behind the +49.0% change in trailing-twelve-month depreciation & amortization. Sequentially, it fell 59.7% from the prior quarter. Over 3 fiscal years it compounded at -12.5% a year.

Context

  • Depreciation & amortization amounted to 1.0% of revenue in FY2025, unchanged from a year earlier.
  • Depreciation & amortization increased in 1 of the last 3 fiscal years.

What to watch

Whether quarterly growth recovers from +45.6% toward the trailing-twelve-month pace of +49.0%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
$447K-59.7% QoQ
Last fiscal yearDec 2025
$2M+7.8% YoY
LTMMar 2026
$2.28M+49.0% YoY
Depreciation & Amortization past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+45.6%——
1 year+7.8%——
3-year CAGR-12.5%——
5-year CAGR——
10-year CAGR——

Depreciation & Amortization history

USD · from the income statement

Latest · FY2025
2M USD
Year-over-year change
+7.8%
4-year CAGR
-10.7%

Depreciation & Amortization vs competitors

How CERS compares with its peers on the latest reported figures

  • Peers report in different currencies, so depreciation & amortization is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +49.0% is the highest of 4, against a peer median of -2.8%.
  • Depreciation & amortization amounts to 1.0% of revenue for CERS, versus a peer median of 6.0%.
CERS Competitors
Depreciation & Amortization for CERS and competitors
Company Period LTM YoY 3-year CAGR% of revenue
GRFSGrifols, S.A.LTM Jun 2026€443.93M EUR+1.5%+1.7%6.0%
HAEHaemonetics CorporationLTM Jun 2026$110.07M USD-4.5%+6.2%8.1%
ADMAADMA Biologics, Inc.LTM Jun 2026$7.69M USD-2.8%+4.4%1.5%
CERSCerus CorporationLTM Mar 2026$2.28M USD+49.0%-12.5%1.0%
Peer median (excluding CERS) —-2.8%+4.4%6.0%

Competitors are the stored peer set for CERS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue130.86M162.05M156.37M180.27M206.13M
Cost of Revenue63.48M74.95M69.97M80.75M95.85M
Gross Profit67.38M87.09M86.4M99.52M110.29M
Gross Margin51.5%53.7%55.3%55.2%53.5%
Research & Development63.69M64.11M67.64M58.91M65.72M
Selling, General & Admin81.29M83.34M75.52M75.89M80.91M
Operating Expenses116.32M121.18M116.45M113.75M146.63M
Depreciation & Amortization3.15M2.98M2.6M1.86M2M
EBITDA(45.99M)(33.52M)(26.34M)(10.02M)(4.94M)
EBITDA Margin-35.1%-20.7%-16.8%-5.6%-2.4%
Operating Income(48.94M)(34.08M)(30.05M)(14.23M)(36.35M)
Operating Margin-37.4%-21.0%-19.2%-7.9%-17.6%
Interest Income00000
Interest Expense4.92M5.83M8.39M8.88M8.34M
Other Income / Expenses(5.12M)(8.26M)(7.27M)(6.53M)21.06M
Income Before Tax(54.06M)(42.34M)(37.32M)(20.76M)(15.28M)
Pre-Tax Margin-41.3%-26.1%-23.9%-11.5%-7.4%
Income Tax Expense319K488K325K205K354K
Net Income(54.37M)(42.78M)(37.49M)(20.92M)(15.63M)
Net Margin-41.6%-26.4%-24.0%-11.6%-7.6%
EPS (Basic)(0.32)(0.24)(0.21)(0.11)(0.08)
EPS (Diluted)(0.32)(0.24)(0.21)(0.11)(0.08)
Weighted Avg Shares171.28M176.55M180.27M184.56M190.59M
Weighted Avg Shares (Diluted)171.28M176.55M180.27M184.56M190.59M

Cerus Corporation

NASDAQ:CERS

Intrinsic Alpha fair value

Locked

Current Price

$1.94

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.